Ailm Biologics

Investors

Ailm Biologics is advancing a first-in-class pro-resolution therapy for complex inflammatory disease — with validated preclinical data, strategic IP, and a clear regulatory path toward the clinic.

Request investor information

Investment thesis

Resolve, don't manage

ABX-90i is designed to restore immune homeostasis and promote tissue repair — not chronic immunosuppression.

Defined, underserved market

Focused entry into IBD with extra-intestinal manifestations, starting with HLA-B27-associated spondyloarthropathies.

Differentiated platform

Plasmid-based therapy targeting microbiome, gut barrier, and immune regulation through HSP90 — with demonstrated preclinical efficacy.

Strong IP & regulatory foundation

100% ownership, full freedom-to-operate in the US and Europe, and EMA Scientific Advice supporting the path to IND.

Market opportunity

Large market with clear unmet need

Focused entry into the high-value complex inflammatory disease segment — a biologically defined, underserved subgroup of IBD patients with systemic disease.

Enteropathic arthritis

0.35 – 1.35 M

patients

~ $3.2 B

market size

IBD with EIM

1.0 – 2.7 M

patients

> $8 B

market size

HLA-B27 associated diseases

32 – 50 M

patients

~ $7.5 B

market size

Milestones

Near-term value inflection

Advancing through CMC completion, Pre-IND submission, and IND-enabling studies — with only two studies required before IND readiness.

Plasmid CMC completed
FDA Pre-IND submitted
Full HLA-B27 rat study on IBD + EIM completed
Ready for IND-enabling studies

Foundation

Regulatory readiness

Scientific Advice for advancing to an IND/IMPD has been obtained from the European Medicines Agency (EMA), providing a validated and clear regulatory pathway forward with the US FDA.

Intellectual property

Ailm Biologics maintains 100% ownership with full freedom-to-operate in both the United States and Europe across two strategic patent families.

HLA-B27 indications — Composition and indications for treatment of HLA-B27 diseases. Priority date: March 31, 2017.
Microflora modulation — Nucleic acid therapy for differential modulation of host microflora. Priority date: September 30, 2020.

Ailm Biologics is a preclinical-stage biotechnology company. Information on this page is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.